Physician profile
Angela Lamb
NPI 1619116654
$521,018.80
in general payments reported to CMS, 2019-2025
33 companies · $348K in 2025
The $348K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $5,372 · 2021: $6,987 · 2022: $6,913 · 2023: $15K · 2024: $127K · 2025: $348K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $352K · Consulting Fee: $76K · Travel and Lodging: $33K · Food and Beverage: $16K · Honoraria: $13K · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $352,265.01 |
| Consulting Fee | $76,067.93 |
| Travel and Lodging | $32,707.95 |
| Food and Beverage | $16,089.32 |
| Honoraria | $12,808.11 |
| Education | $111.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $129,779.02 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Lilly USA, LLC | $124,663.94 | 2023-2025 | Ebglyss, Taltz, Olumiant |
| Pfizer INC. | $85,225.06 | 2019-2025 | |
| Leo Pharma INC. | $45,145.32 | 2019-2025 | Adbry, Anzupgo, Spevigo |
| Abbvie INC. | $42,161.81 | 2019-2025 | |
| Botanix Sb INC | $34,235.98 | 2025 | Sofdra |
| Ucb, INC. | $21,623.96 | 2019-2025 | Bimzelx |
| Organon LLC | $13,136.32 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $6,929.85 | 2019-2025 | Jublia, Cabtreo |
| Incyte Corporation | $6,022.63 | 2021-2025 | Opzelura, Opzelura |
| Eli Lilly and Company | $5,950.00 | 2025 | Ebglyss |
| Regeneron Healthcare Solutions, INC. | $1,017.15 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $792.54 | 2019-2025 | |
| Dermavant Sciences, INC. | $726.07 | 2022-2024 | Vtama |
| Janssen Biotech, INC. | $558.71 | 2019-2025 | Tremfya |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $491.89 | 2022-2025 | Sotyktu |
| Revance Therapeutics, INC. | $409.95 | 2024-2025 | Daxxify |
| Novartis Pharmaceuticals Corporation | $386.89 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $298.67 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $296.72 | 2024-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $240.39 | 2020-2025 | Winlevi, Absorica Ld |
| Almirall LLC | $179.96 | 2020-2022 | |
| Amgen INC. | $148.71 | 2021-2025 | Otezla, Otezla |
| Dermira, INC. | $131.46 | 2019-2021 | |
| Merz North America, INC. | $116.61 | 2021 | |
| Vyne Pharmaceuticals INC. | $109.77 | 2021 | |
| Allergan, INC. | $89.44 | 2019-2022 | |
| Journey Medical Corporation | $44.87 | 2020-2024 | |
| Lnhc, INC | $23.25 | 2025 | Zelsuvmi |
| Mayne Pharma Commercial LLC | $23.23 | 2019 | |
| Verrica Pharmaceuticals INC. | $22.36 | 2023 | Ycanth |
| Medtronic Vascular, INC. | $18.41 | 2019 | |
| Mylan Pharmaceuticals INC. | $17.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Lamb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.